AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05237830 — intervention group
Intervention type: PROCEDURE
Intervention: Use of Cell Salvage in revision of total hip arthroplasty
Description: The effective use of the cell saver was defined as the ability to re-transfuse at least 125 mL of re-suspended red blood cells with a hematocrit of 60 %.
Study NCT03879187 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-fat, high-energy diet
Description: Participants consumed a diet that was high in fat and high in energy
Study NCT03313713 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beta-glucans
Description: Placebo consumption at breakfast (3 g per day)
Study NCT03313713 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consumption at breakfast (3 g per day)
Study NCT02472834 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino acid supplementation NephrAmine®
Description: Dialysis patients will be randomized to receive either 250 mL of NephrAmine® (5.4% amino acids for injection; B. Braun Medical, Inc) containing \~14 grams of essential amino acids during each dialysis session (3 times weekly for 8 weeks) or no treatment (standard-of-care)
Study NCT03438422 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pollen extract
Description: 1 tablet a day
Study NCT00520572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9056
Study NCT00520572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Study NCT00520572 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00960856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibric Acid 105 mg Tablet
Description: One 105 mg tablet administered 30 minutes after the initiation of a low-fat breakfast.
Study NCT00960856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibric Acid 105 mg Tablet
Description: One 105 mg tablet administered 30 minutes after the initiation of a standard breakfast
Study NCT00960856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibric Acid 105 mg Tablet
Description: One 105 mg tablet administered 30 minutes after the initiation of a high-fat/high-calorie breakfast.
Study NCT00960856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibric Acid 105 mg Tablet
Description: One 105 mg tablet administered after an overnight fast of at least 10 hours.
Study NCT03347539 — intervention group
Intervention type: DEVICE
Intervention: Nexplaon
Description: This study is an exploratory study of user reasons for Nexplanon implant and removal, and NOT a study on the efficacy or safety of Nexplanon. Nexplanon has already been FDA approved and its efficacy and safety studied.
Study NCT03664609 — intervention group
Intervention type: DEVICE
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation in patients with Parkinson Disease, Dystonia and Essential Tremor.
Study NCT03383367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tempo Colo
Description: Reminder letter for people at high risk of colorectal cancer.
Study NCT00737984 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial sampling
Description: Endometrial sampling performed in the preceding cycle. It will be done in the follicular phase not later than day 10 of the cycle
Study NCT02005003 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Inhibitory task
Description: Participants perform a binary decision on each presented stimuli. Of the two possible outcomes, participants are instructed to make a motor response (go) for one type, and are to withhold a response (no-go) for the other type. Reaction time and accuracy are measured for each event
Study NCT02005003 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inhibitory task
Description: Participants perform a binary decision on each presented stimuli. Of the two possible outcomes, participants are instructed to make a motor response (go) for one type, and are to withhold a response (no-go) for the other type. Reaction time and accuracy are measured for each event
Study NCT02005003 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood samples
Description: Hormone levels will be analyzed from blood samples obtained before and after a caloric preload given at each visit
Study NCT02005003 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples
Description: Hormone levels will be analyzed from blood samples obtained before and after a caloric preload given at each visit
Study NCT02005003 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Feces collection
Description: Feces samples will be collected on the morning of each visit, before and after each 2-week intervention period, as well as after each 2-week washout period following each intervention period.
Study NCT02005003 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Feces collection
Description: Feces samples will be collected on the morning of each visit, before and after each 2-week intervention period, as well as after each 2-week washout period following each intervention period.
Study NCT02005003 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Caloric preload
Description: A caloric preload will be given to participants, following which blood will be taken at 65 minutes later (specified in Blood sampling) following the ingestion of the caloric preload.
Study NCT02005003 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caloric preload
Description: A caloric preload will be given to participants, following which blood will be taken at 65 minutes later (specified in Blood sampling) following the ingestion of the caloric preload.
Study NCT02005003 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Food selection task
Description: Participants are given the opportunity to write and use a computer program to specify amount and type of food would ideally like to consume
Study NCT02005003 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food selection task
Description: Participants are given the opportunity to write and use a computer program to specify amount and type of food would ideally like to consume
Study NCT02005003 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Memory task
Description: Participants perform short memory tasks on each visit
Study NCT02005003 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Memory task
Description: Participants perform short memory tasks on each visit
Study NCT02005003 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Food consumption task
Description: Participants are given a selection of food items to consume on each visit
Study NCT02005003 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food consumption task
Description: Participants are given a selection of food items to consume on each visit
Study NCT00943878 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: Licensed trivalent influenza vaccine (TIV) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.
Study NCT00943878 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated H1N1 Vaccine
Description: Two doses of inactivated influenza H1N1 vaccine, 15 mcg per dose, administered as a single 0.5 milliliters (mL) intramuscular injection in the deltoid muscle.
Study NCT00943878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline (placebo control) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.
Study NCT01292395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Protein Intake
Description: Protein intakes within the current recommendation
Study NCT01977534 — intervention group
Intervention type: DEVICE
Intervention: Absorb BVS
Description: The Absorb BVS System is a bioresorbable poly(L-lactide) (PLLA) scaffold with a drug and bioresorbable polymer coating \[formulation of everolimus in a bioresorbable poly(D,L-lactide) (PDLLA) coating\].
Study NCT03415074 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Protein restriction
Description: In both arms the dietary protein intake will be reduced. In the sLPD arm, the protein restriction is more severe and ketoanalogues of the essential aminoacids are offered.
Study NCT02204540 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mock study intervention
Description: Participants will swallow a pill and consume food in a mock research study, while their performance of the task is being monitored.
Study NCT02204540 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mock study intervention
Description: Participants will swallow a pill and consume food in a mock research study, while their performance of the task is being monitored.
Study NCT01747330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancreatin
Description: Doses of Pancreatin \<2500 lipase u/kg/feed or \<4000 lipase U/g fat/intake or \<10000 lipase U/kg/day given orally are used
Study NCT03330691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Patient-derived CD19- and CD22 specific CAR
Description: Patient-derived CD19-specific CAR also expressing an HER2t and CD22-specific CAR T-cells also expressing an EGFRt
Study NCT04616118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Visit
Description: Participants randomized to this arm will receive usual care via telephone only
Study NCT04616118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Visit
Description: Participants randomized to this arm will receive usual care via video call
Study NCT01011790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healing Rhythms™ Meditation Program
Description: The Healing Rhythms™ meditation program was chosen as the intervention for this study because it has a long history of use in the consumer market, it provides a dual-mode biofeedback which allows users to visually see their progress, and it provides an attractive and engaging user interface which is enjoyable to use. This is a critical factor as the research cited documents the importance of adherence in achieving optimal outcomes.
Study NCT03157102 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: Oxygen therapy will be delivered through high flow nasal cannulas. Aerosol treatments will be administered through a vibrating mesh nebulizer directly connected to the circuit (aerogen®). The airvo® system (Fisher \& Peykel Healthcare, Auckland, New Zealand) will be used as the high flow cannula system in the study. Cannula size will be tailored to the child according to the manufacturer's recommendations. The gas flow will be adjusted according to the child's weight in a predefined chart. FiO2 will be adjusted to allow for a SpO2 >92%.~All the patients, regardless of their treatment failure status, will be evaluated at H2, H6, H12 and H24 to monitor their evolution (evaluation of the standard parameters, consciousness, PRAM (Pediatric Respiratory Assessment Measure) score, pain assessment by the FLACC (Face Legs Activity Cry Consolability) score). .
Study NCT03157102 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard Oxygen Treatment
Description: Children will receive supplemental oxygen as commonly delivered through a non-rebreather face mask or low flow nasal cannula (standard oxygen treatment) and beta2 agonist aerosol via vibrating mesh nebulizer (aerogen®) according to the procedures usually used in the unit and according to the GINA (Global Initiative for Asthma) protocol. This group is the standard treatment group and is therefore the control group.~All the patients, regardless of their treatment failure status, will be evaluated at H2, H6, H12 and H24 to monitor their evolution (evaluation of the standard parameters, consciousness, PRAM score, pain assessment by the FLACC score). The use of adjuvant therapies (magnesium sulfate, salbutamol IVSE, and ipratropium bromide) will remain at the discretion of the physician in charge of the child and will be evaluated as a secondary criterion.
Study NCT02359253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive stretching
Description: Prior to active training, subjects will be passively move their arm or hand by IntelliArm or the hand robot within preset ranges of motion.
Study NCT02359253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive movement
Description: Prior to active training, subjects will be passively move their arm or hand by IntelliArm or the hand robot only within ranges that produce no to very minimal forces.
Study NCT00452218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 200 mg daily and dose escalated to a maximum of 400 mg twice daily
Study NCT03816449 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: exercises
Description: Aerobic exercise will be conducted as a dose walk, 3-5 km / h, lasting 50 minutes per day, least five days per week, for 12 weeks. The intensity of the training will be around 70% of the maximal heart rate.~Resistance training and balance exercises will be conducted as a group program and will involve exercises to strengthen the muscles of the upper and lower extremities and balance exercises. The intensity of the training will be increased on weekly, starting from 3-5 repeating load and its own weight, up to 8-12 repetitions and load straps. Progression and maintenance load tapes will be carried out depending on the capacity of individualized persons. Frequency of training will be 3 times a week,will last 70 minutes per day for 12 weeks.
Study NCT03816449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercises
Description: Aerobic exercise will be conducted as a dose walk, 3-5 km / h, lasting 50 minutes per day, least five days per week, for 12 weeks. The intensity of the training will be around 70% of the maximal heart rate.~Resistance training and balance exercises will be conducted as a group program and will involve exercises to strengthen the muscles of the upper and lower extremities and balance exercises. The intensity of the training will be increased on weekly, starting from 3-5 repeating load and its own weight, up to 8-12 repetitions and load straps. Progression and maintenance load tapes will be carried out depending on the capacity of individualized persons. Frequency of training will be 3 times a week,will last 70 minutes per day for 12 weeks.
Study NCT04197154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Threat manipulation (control, no threat)
Description: Before the start of conditioning, a mock skin-sensitivity test informs participants that their skin reacts to heat normally and it is safe for them to participate. A skin-sensitivity reading shows participants a scale that is in the green (no danger) zone.
Study NCT04197154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Threat manipulation
Description: Before the start of conditioning, a mock skin-sensitivity test informs participants that their skin is very sensitive and their nerve fibers are very responsive and they may have adverse reactions to the heat-pain application. A skin-sensitivity reading shows participants a scale that is in the red (higher danger) zone.
Study NCT04197154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditioning of moderate pain
Description: During nocebo trials of the acquisition phase, conditioned stimuli (i.e., on-screen visual cues ON signaling the activation of sham electrical stimulation) are paired to unconditioned moderate-pain stimuli, to induce a negative association between the activation of electrical stimuli and an increase in pain. During control trials of the acquisition phase, the deactivation of the sham electrical stimulation (i.e., on-screen message OFF) is paired to 'baseline' pain of lower intensity.
Study NCT04197154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditioning of high pain
Description: During nocebo trials of the acquisition phase, conditioned stimuli (i.e., on-screen visual cues ON signaling the activation of sham electrical stimulation) are paired to unconditioned high-pain stimuli, to induce a negative association between the activation of electrical stimuli and an increase in pain. During control trials of the acquisition phase, the deactivation of the sham electrical stimulation (i.e., on-screen message OFF) is paired to pain of lower intensity.
Study NCT04197154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extinction
Description: During extinction, the previously conditioned nocebo effects on pain are attenuated by pairing the nocebo and control visual cues (i.e., on-screen messages ON and OFF) to pain stimuli of only lower intensity.
Study NCT02575456 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ebola Vaccine
Study NCT02575456 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: control
Study NCT03103711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Intervention
Description: Participants receive two sessions oriented to joy and two focused on relax. In the first 2 sessions patients can choose the environment (Emotional Parks or Walk through Nature) and in the following ones participants visit the alternate environments.
Study NCT02504775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mejoral® 500 Tablets
Description: 500 mg tablet of paracetamol
Study NCT01375309 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium bifidum supplementation
Description: Bifidobacterium bifidum supplementation wiht approximately 2.5\*10to9th bacteria per day
Study NCT01375309 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo contains dextrin
Description: 0.5 of dextrin
Study NCT01828294 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Subcutaneous immunoglobulins
Description: Immunoglobulins used subcutaneously for maintenance of other immune mediated disorders.
Study NCT01208194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGN1703
Description: solution, 60 mg, twice a week, until progression
Study NCT01208194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: solution, 60 mg, twice a week, until progression
Study NCT03892343 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiac Magnetic Resonance Imaging (Siemens Skyra 3T): will be performed using protocols and techniques already in use in our group. All CMR scan derived parameters will be analysed with the investigator blinded to treatment allocation as in previous studies.
Study NCT01120028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab 30 mg intravenously or subcutaneously, two doses 24 hours apart
Study NCT01120028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: 20 mg intravenously, two doses 96 hours apart
Study NCT02504775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tylenol® Caplets
Description: 500 mg tablet of paracetamol
Study NCT02182453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 - single rising dose
Study NCT02182453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02359253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IntelliArm
Description: During the active training, subjects will be asked to actively move their arm while supported with IntelliArm robot to interact with virtual targets and objects. The IntelliArm may provide resistance or assistance.
Study NCT02359253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand robot
Description: During the active training, subjects will be asked to actively open and close their hand with the hand robot on while participating in task oriented occupational therapy focused on grasp and release tasks. The hand robot may provide resistance or assistance.
Study NCT03662893 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioural therapy with written checklist form to complete
Description: Behavioural therapy for overactive bladder such as advice on fluid balance, bladder retraining, urgency suppression or normal voiding techniques, pelvic floor muscle training, caffeine reduction, dietary changes, weight loss and other life style changes
Study NCT03662893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antimuscarinic drugs used in overactive bladder
Description: Antimuscarinic drugs (Tolterodine, solifenacin, propiverine, darifenacin,fesoterodine)
Study NCT03662893 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: behavioural therapy with written guideline
Description: behavioural therapy with written guideline,which are the same as those in the checklist
Study NCT03662893 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioural therapy with written guideline
Description: behavioural therapy with written guideline,which are the same as those in the checklist
Study NCT00159510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylene blue
Description: Injection bolus of 2 mg/kg PBW and infusion of 0.2 mg/kg/hr
Study NCT00159510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric oxide
Description: An inhalation of NO via ETT at 10 ppm, partially weaned by 72 hrs of therapy
Study NCT00159510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylene blue & nitric oxide
Description: See the dosage in the previous arms
Study NCT00885495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darunavir, ritonavir, rosuvastatin
Description: darunavir 600 mg twice daily for 7 days ritonavir 100 mg twice daily for 7 days rosuvastatin 10 mg once daily for 7 days Combination of all three drugs for 7 days